Immuneering Corp. announced encouraging updated survival and safety outcomes from its ongoing Phase IIa trial combining oral MEK inhibitor atebimetinib with modified gemcitabine/nab-paclitaxel in first-line pancreatic cancer patients. At nine months median follow-up, survival data suggest positive therapeutic impact. The company plans detailed presentations at the Pancreatic Cancer Action Network Scientific Summit, highlighting its progress in addressing one of the most challenging solid tumors.